Orlistat(Orli) is a safe and effective drug for obesity treatment approved by the Food and Drug Administration (FDA) in the US. Recently, Orli has been reported to exert considerable antitumor effects in amount types of malignancy. However, its role in osteosarcoma (OS) progression and its clinical significance in tumor therapy such as immune therapy remains largely unknown. In this study, we detected the effect of Orli exerted on OS progression using CCK-8 assay, wound-healing assay, Enzyme-linked immunosorbent assay (ELISA), cell transfection and xenograft growth assay. The result indicated that by upregulating Serpin Family F member 1 (SERPINF1), a multifunctional protein, OS inhibited OS progression via suppressing proliferation, colony-forming, migration and angiogenesis ability of OS cells in vitro and in vivo. More importantly, Orli potentiated programmed death1 antibody (PD1ab) immune checkpoint blockade therapy and may candidate as a potential drug in OS therapy.
Wang et al. (Thu,) studied this question.